Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma  

作　　者：Masatoshi Kudo 

机构地区：[1]Department of Gastroenterology and Hepatology,Kindai University Faculty of Medicine,Osaka-Sayama,Japan

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第3期435-439,共5页肝胆外科与营养（英文）

摘　　要：Hepatectomy and radiofrequency ablation(RFA)are established curative methods for hepatocellular carcinoma(HCC).However,the recurrence rate of HCC is high even in patients who undergo these curative therapies,with HCC recurrence observed in approximately 80%of patients five years after curative therapy with RFA(1).Pathological studies have identified microscopic intrahepatic metastases of a single lesion measuring<2 cm after resection of HCC in approximately 10%of patients and microvascular invasion in approximately 27%of cases(2),highlighting the risk of intrahepatic metastatic recurrence even for single small HCCs measuring<2 cm.For HCCs≥2 cm,the risk of intrahepatic metastasis and microvascular invasion increases with tumor size and number,concurrently increasing the risk of intrahepatic metastatic recurrence(3).

关 键 词：Hepatocellular carcinoma atezolizumab plus bevacizumab adjuvant therapy RESECTION ablation 

分 类 号：R735.7[医药卫生—肿瘤]